The company plans to consolidate a number of R&D sites and functions with the loss of 2,100 jobs in Europe and 700 in the US, primarily within Takeda Pharmaceuticals North America.
Yasuchika Hasegawa, President and CEO, Takeda, says the changes are needed to ensure “efficient and flexible operations moving forward”.
The company estimates the restructuring plans will cost approximately 70 billion Yen and generate cost synergies of approximately Yen 200 billion by 2015.
The intention to align its workforce, consolidate site operations, and strengthen its global presence was first outlined in the company’s 2011-2013 Mid-Range Plan. Takeda says its latest streamlining measures will bring further efficiencies to sustain medium and long-term growth targets starting in 2015.
It now plans to align Nycomed’s former operation structures and processes with its own global headquarters in Japan and the newly defined organisations of the Chief Commercial Officer and Chief Medical & Scientific Officer, and its expanded affiliate network worldwide.
Takeda will also adopt a new strategy away from a product portfolio focused on mature, high selling products to a more diverse range of treatments. In order to do this, Takeda will invest in R&D on core therapeutic areas, while using internal and external resources to create new innovative products.